To manufacture and market Galvus and Galvus combination brands, used in the treatment of type 2 diabetes from January 1, 2026
Cipla has signed a perpetual license agreement with Novartis Pharma (Switzerland) to manufacture and market Galvus and Galvus combination brands, used in the treatment of type 2 diabetes from January 1, 2026. The agreement is subject to satisfaction of certain conditions precedent.
Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category. Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs 268 crore.
This deal is expected to further bolster Cipla’s position in India as one of the top players in the diabetes category.